# Florence S H Wong

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 161 papers | 13,337 citations | 28190 55 h-index | 23472 111 g-index |
| 168 all docs | 168 docs citations | 168 times ranked | 7036 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38, 258-266. | 3.6 | 744 |
| 2 | Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 2015, 62, 968-974. | 1.8 | 571 |
| 3 | Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgraduate Medical Journal, 2008, 84, 662-670. | 0.9 | 504 |
| 4 | Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. Gastroenterology, 2007, 133, 825-834. | 0.6 | 494 |
| 5 | Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60, 250-256. | 3.6 | 456 |
| 6 | Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31, 207-210. | 3.6 | 435 |
| 7 | The North American Study for the Treatment of Refractory Ascites. Gastroenterology, 2003, 124, 634-641. | 0.6 | 424 |
| 8 | Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537. | 6.1 | 405 |
| 9 | Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2004, 40, 55-64. | 3.6 | 369 |
| 10 | Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology, 1995, 21, 1238-1247. | 3.6 | 366 |
| 11 | Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut, 2011, 60, 702-709. | 6.1 | 359 |
| 12 | Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology, 2012, 56, 2328-2335. | 3.6 | 357 |
| 13 | Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology, 2006, 44, 1535-1542. | 3.6 | 349 |
| 14 | Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74, 1014-1048. | 3.6 | 311 |
| 15 | Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10. | 0.6 | 296 |
| 16 | A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology, 2003, 37, 182-191. | 3.6 | 269 |
| 17 | Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. New England Journal of Medicine, 2021, 384, 818-828. | 13.9 | 235 |
| 18 | Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150, 1579-1589.e2. | 0.6 | 225 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites. Annals of Internal Medicine, 1995, 122, 816. | 2.0 | 223 |
| 20 | New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. Gastroenterology, 2013, 145, 1280-1288.e1. | 0.6 | 221 |
| 21 | Acute kidney injury in decompensated cirrhosis. Gut, 2013, 62, 131-137. | 6.1 | 205 |
| 22 | NACSELD acuteâ€onâ€chronic liver failure (NACSELDâ€ACLF) score predicts 30â€day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374. | 3.6 | 197 |
| 23 | The 3â€month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology, 2016, 64, 200-208. | 3.6 | 189 |
| 24 | Effects of satavaptan, a selective vasopressin V<sub>2</sub>receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology, 2008, 48, 204-213. | 3.6 | 183 |
| 25 | Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut, 2021, 70, 531-536. | 6.1 | 178 |
| 26 | Cirrhotic cardiomyopathy. Hepatology International, 2009, 3, 294-304. | 1.9 | 172 |
| 27 | Hepatorenal syndrome. Nature Reviews Disease Primers, 2018, 4, 23. | 18.1 | 172 |
| 28 | Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver International, 2010, 30, 937-947. | 1.9 | 161 |
| 29 | The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt. American Journal of Gastroenterology, 2009, 104, 2458-2466. | 0.2 | 160 |
| 30 | Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Critical Care, 2012, 16, R23. | 2.5 | 145 |
| 31 | The hyperdynamic circulation in cirrhosis. , 2001, 89, 221-231. | | 127 |
| 32 | Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transplantation, 2015, 21, 300-307. | 1.3 | 122 |
| 33 | Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116. | 6.1 | 121 |
| 34 | Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clinical Science, 1999, 97, 259-267. | 1.8 | 109 |
| 35 | Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 753-759.e2. | 2.4 | 105 |
| 36 | Recent advances in our understanding of hepatorenal syndrome. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 382-391. | 8.2 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. American Journal of Gastroenterology, 2001, 96, 2442-2447. | 0.2 | 90 |
| 38 | Acute-on-Chronic Liver Failure Clinical Guidelines. American Journal of Gastroenterology, 2022, 117, 225-252. | 0.2 | 90 |
| 39 | Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 756-765.e3. | 2.4 | 89 |
| 40 | Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. American Journal of Gastroenterology, 2018, 113, 556-563. | 0.2 | 87 |
| 41 | Acuteâ€onâ€Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology, 2018, 68, 1621-1632. | 3.6 | 86 |
| 42 | Central blood volume in cirrhosis: Measurement with radionuclide angiography. Hepatology, 1994, 19, 312-321. | 3.6 | 83 |
| 43 | Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut, 2010, 59, 381-386. | 6.1 | 83 |
| 44 | Bacterial infections in end-stage liver disease: current challenges and future directions. Gut, 2012, 61, 1219-1225. | 6.1 | 81 |
| 45 | New challenge of hepatorenal syndrome: Prevention and treatment. Hepatology, 2001, 34, 1242-1251. | 3.6 | 78 |
| 46 | Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. Journal of Hepatology, 2010, 53, 283-290. | 1.8 | 78 |
| 47 | Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339. | 1.8 | 76 |
| 48 | Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. Gastroenterology, 1995, 108, 1820-1827. | 0.6 | 68 |
| 49 | Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. Clinical Science, 2001, 101, 621-628. | 1.8 | 68 |
| 50 | Drug Insight: the role of albumin in the management of chronic liver disease. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 43-51. | 1.7 | 68 |
| 51 | Management of ascites in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 11-20. | 1.4 | 68 |
| 52 | Longâ€term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 389-395. | 1.4 | 66 |
| 53 | Acute kidney injury in liver cirrhosis: new definition and application. Clinical and Molecular Hepatology, 2016, 22, 415-422. | 4.5 | 65 |
| 54 | Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology, 2020, 159, 1715-1730.e12. | 0.6 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites22Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. American Journal of Medicine, 1999, 106, 315-322. | 0.6 | 63 |
| 56 | Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1821-1830.e6. | 2.4 | 61 |
| 57 | High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of endâ€stage liver disease. Liver Transplantation, 2015, 21, 881-888. | 1.3 | 59 |
| 58 | Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology, 1993, 104, 884-889. | 0.6 | 55 |
| 59 | Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation, 2019, 25, 870-880. | 1.3 | 55 |
| 60 | Terlipressin Improves Renal Function and Reverses HepatorenalÂSyndrome in Patients With Systemic InflammatoryÂResponseÂSyndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 266-272.e1. | 2.4 | 53 |
| 61 | Outcomes After Listing for Liver Transplant in Patients With Acuteâ€onâ€Chronic Liver Failure: The Multicenter North American Consortium for the Study of Endâ€Stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579. | 1.3 | 53 |
| 62 | Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology, 1994, 20, 873-881. | 3.6 | 51 |
| 63 | Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 45-51. | 3.7 | 48 |
| 64 | Refractory Ascites in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, 40-47. | 0.2 | 46 |
| 65 | The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339. | 0.2 | 44 |
| 66 | Beta-blockers in cirrhosis: Friend and foe?. Hepatology, 2010, 52, 811-813. | 3.6 | 43 |
| 67 | The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology, 1998, 115, 397-405. | 0.6 | 42 |
| 68 | The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology, 2002, 35, 1449-1458. | 3.6 | 42 |
| 69 | Pathways of hepatic and renal damage through nonâ€classical activation of the reninâ€angiotensin system in chronic liver disease. Liver International, 2020, 40, 18-31. | 1.9 | 42 |
| 70 | Model for Endâ€Stage Liver Diseaseâ€Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology, 2020, 72, 1747-1757. | 3.6 | 42 |
| 71 | Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology, 2007, 47, 160-168. | 3.6 | 41 |
| 72 | Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100. | 0.2 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The use of TIPS in chronic liver disease. Annals of Hepatology, 2006, 5, 5-15. | 0.6 | 40 |
| 74 | Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clinical Science, 1999, 97, 259. | 1.8 | 38 |
| 75 | Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance. Hepatology, 1995, 22, 358-364. | 3.6 | 36 |
| 76 | The evolving concept of acute kidney injury in patients with cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 711-719. | 8.2 | 35 |
| 77 | New diagnostic criteria and management of acute kidney injury. Journal of Hepatology, 2017, 66, 860-861. | 1.8 | 35 |
| 78 | Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. Hepatology, 2021, 74, 2699-2713. | 3.6 | 27 |
| 79 | Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. Metabolic Brain Disease, 2013, 28, 301-305. | 1.4 | 26 |
| 80 | A cut-off serum creatinine value of 1.5 mg/dl for AKI â€“ To be or not to be. Journal of Hepatology, 2015, 62, 741-743. | 1.8 | 25 |
| 81 | An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Review of Gastroenterology and Hepatology, 2019, 13, 293-305. | 1.4 | 25 |
| 82 | Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVIDâ€19: A Multicenter Cohort. Liver Transplantation, 2021, 27, 1343-1347. | 1.3 | 25 |
| 83 | Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clinical Gastroenterology and Hepatology, 2019, 17, 2339-2346.e1. | 2.4 | 24 |
| 84 | Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. Clinical Science, 2001, 101, 621. | 1.8 | 23 |
| 85 | Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. Transplantation, 2015, 99, 1441-1446. | 0.5 | 23 |
| 86 | Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. Digestive Diseases and Sciences, 2016, 61, 3084-3092. | 1.1 | 23 |
| 87 | Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e1-e5. | 0.2 | 22 |
| 88 | Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. Nephrology Dialysis Transplantation, 2020, 35, 1554-1561. | 0.4 | 22 |
| 89 | Ascites and Hepatorenal Syndrome. Clinics in Liver Disease, 2019, 23, 659-682. | 1.0 | 20 |
| 90 | Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211026. | 1.4 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology, 1993, 18, 519-528. | 3.6 | 19 |
| 92 | Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. Digestive Diseases and Sciences, 2017, 62, 768-776. | 1.1 | 19 |
| 93 | Improvement in Quality of Life and Decrease in Largeâ€Volume Paracentesis Requirements With the Automated Lowâ€Flow Ascites Pump. Liver Transplantation, 2020, 26, 651-661. | 1.3 | 19 |
| 94 | Variations in albumin use in patients with cirrhosis: An AASLD members survey. Hepatology, 2015, 62, 1923-1924. | 3.6 | 18 |
| 95 | REVIEW: The controversy over the pathophysiology of ascites formation in cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 437-444. | 1.4 | 17 |
| 96 | Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2019, 114, 599-606. | 0.2 | 17 |
| 97 | Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Digestive Diseases and Sciences, 2020, 65, 2571-2579. | 1.1 | 17 |
| 98 | Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. American Journal of Gastroenterology, 2021, 116, 336-346. | 0.2 | 17 |
| 99 | Liver and kidney diseases. Clinics in Liver Disease, 2002, 6, 981-1011. | 1.0 | 16 |
| 100 | Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Digestive Diseases and Sciences, 2021, 66, 3612-3618. | 1.1 | 15 |
| 101 | The use of TIPS in chronic liver disease. Annals of Hepatology, 2006, 5, 5-15. | 0.6 | 15 |
| 102 | Unâ€precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. Liver International, 2018, 38, 1785-1792. | 1.9 | 14 |
| 103 | Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. Clinical Gastroenterology and Hepatology, 2021, 19, 1661-1669.e2. | 2.4 | 14 |
| 104 | Acute kidney injury: prediction, prognostication and optimisation for liver transplant. Hepatology International, 2020, 14, 167-179. | 1.9 | 14 |
| 105 | COVIDâ€19 and Liver Cirrhosis: Focus on the Nonclassical Reninâ€Angiotensin System and Implications for Therapy. Hepatology, 2021, 74, 1074-1080. | 3.6 | 14 |
| 106 | Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges?. Hepatology, 2005, 42, 533-535. | 3.6 | 13 |
| 107 | Renal Diseases and the Liver. Clinics in Liver Disease, 2011, 15, 39-53. | 1.0 | 13 |
| 108 | Renal Dysfunction After Liver Transplantation: Effect of Donor Type. Liver Transplantation, 2020, 26, 799-810. | 1.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). Antiviral Therapy, 2019, 24, 35-44. | 0.6 | 12 |
| 110 | Treatment of Oesophageal Varices in Liver Cirrhosis. Digestion, 2019, 99, 261-266. | 1.2 | 12 |
| 111 | Central blood volume in cirrhosis: Measurement with radionuclide angiography. Hepatology, 1994, 19, 312-321. | 3.6 | 12 |
| 112 | Hepatorenal syndrome: Current management. Current Gastroenterology Reports, 2008, 10, 22-29. | 1.1 | 11 |
| 113 | Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acuteâ€onâ€Chronic Liver Failure. Clinical Liver Disease, 2019, 14, 92-97. | 1.0 | 11 |
| 114 | The Prediction of Inâ€Hospital Mortality in Decompensated Cirrhosis with Acuteâ€onâ€Chronic Liver Failure. Liver Transplantation, 2022, 28, 560-570. | 1.3 | 11 |
| 115 | Diagnosing and treating renal disease in cirrhotic patients. Minerva Gastroenterologica E Dietologica, 2016, 62, 253-66. | 2.2 | 11 |
| 116 | Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis. Hepatology, 2014, 60, 455-457. | 3.6 | 10 |
| 117 | THE PATHOPHYSIOLOGIC BASIS FOR THE TREATMENT OF CIRRHOTIC ASCITES. Clinics in Liver Disease, 2001, 5, 819-832. | 1.0 | 9 |
| 118 | Medical management of ascites. Expert Opinion on Pharmacotherapy, 2011, 12, 1269-1283. | 0.9 | 9 |
| 119 | Effects of Sodium Status on the Venous Response to Noradrenaline Infusion in Pre-Ascitic Cirrhosis. Clinical Science, 1995, 88, 525-531. | 1.8 | 8 |
| 120 | Definition and Diagnosis of Acute Kidney Injury in Cirrhosis. Digestive Diseases, 2015, 33, 539-547. | 0.8 | 7 |
| 121 | Utility of shearâ€wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. Journal of Clinical Ultrasound, 2018, 46, 311-318. | 0.4 | 7 |
| 122 | Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 565-572.e5. | 2.4 | 7 |
| 123 | Latest Treatment of Acute Kidney Injury in Cirrhosis. Current Treatment Options in Gastroenterology, 2020, 18, 281-294. | 0.3 | 7 |
| 124 | Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. Clinical Gastroenterology and Hepatology, 2023, 21, 1031-1040.e3. | 2.4 | 7 |
| 125 | Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. Clinical Science, 1999, 96, 467-474. | 1.8 | 6 |
| 126 | Hepatorenal Syndrome: Do the Vasoconstrictors Work?. Gastroenterology Clinics of North America, 2011, 40, 581-598. | 1.0 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The impact of acute kidney injury in cirrhosis: does definition matter?. Gut, 2013, 62, 1091.2-1092. | 6.1 | 6 |
| 128 | Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. Nutrients, 2019, 11, 2379. | 1.7 | 5 |
| 129 | Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. Hepatology, 2019, 70, 450-451. | 3.6 | 5 |
| 130 | Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. Journal of Vascular and Interventional Radiology, 2020, 31, 1256-1262.e3. | 0.2 | 5 |
| 131 | Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver International, 2020, 40, 2385-2393. | 1.9 | 5 |
| 132 | Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis*1. Hepatology, 1995, 21, 717-724. | 3.6 | 4 |
| 133 | Does Losartan Work After All?. American Journal of Gastroenterology, 2003, 98, 1222-1224. | 0.2 | 4 |
| 134 | The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. Hepatology, 2006, 44, 640-649. | 3.6 | 4 |
| 135 | Treatment to Improve Acute Kidney Injury in Cirrhosis. Current Treatment Options in Gastroenterology, 2015, 13, 235-248. | 0.3 | 4 |
| 136 | Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed: Medscape General Medicine, 2004, 6, 9. | 0.2 | 4 |
| 137 | Excess nitric oxide in preascites: another piece in the puzzle. American Journal of Gastroenterology, 2002, 97, 2167-2169. | 0.2 | 3 |
| 138 | SAT-141-The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start?. Journal of Hepatology, 2019, 70, e692-e693. | 1.8 | 3 |
| 139 | Portal hypertensive gastropathy. Gastroenterology and Hepatology, 2007, 3, 428-73. | 0.2 | 3 |
| 140 | Acute renal dysfunction in liver cirrhosis. Gastroenterology and Hepatology, 2013, 9, 830-2. | 0.2 | 2 |
| 141 | Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International, 2022, , . | 1.9 | 2 |
| 142 | Acute-on-Chronic Liver Failure. American Journal of Gastroenterology, 2022, 117, 831-834. | 0.2 | 2 |
| 143 | The Role of Liver Biopsy in the Management of Patients with Liver Disease. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 651-654. | 1.8 | 1 |
| 144 | Renal Failure in Cirrhosis. , 2018, , 262-280.e5. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation. Journal of Hepatology, 2019, 70, e691-e692. | 1.8 | 1 |
| 146 | Reply to: Correspondence on â€œClinical features and evolution ofÂbacterial infection-related acute-on-chronic liver failureâ€. Journal of Hepatology, 2021, 75, 1010-1012. | 1.8 | 1 |
| 147 | Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology, 1993, 18, 519-528. | 3.6 | 1 |
| 148 | Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. , 2018, 38, 1785. | | 1 |
| 149 | Management of Ascites. , 2005, , 301-317. | | 1 |
| 150 | Hepatorenal Syndrome: Are We Doing Better?. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 121-122. | 1.8 | 0 |
| 151 | Vaptans for Ascites â€“ Chances and Risks. Frontiers of Gastrointestinal Research, 2010, , 91-101. | 0.1 | 0 |
| 152 | Speckle tracking echocardiography in cirrhosis: is it ready for prime time?. Hepatology International, 2014, 8, 10-13. | 1.9 | 0 |
| 153 | EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. Journal of Hepatology, 2014, 61, 469-471. | 1.8 | 0 |
| 154 | Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?. Hepatology International, 2016, 10, 390-393. | 1.9 | 0 |
| 155 | IDDF2018-ABS-0067â€…Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study. , 2018, , . | | 0 |
| 156 | Reply. Liver Transplantation, 2019, 25, 1586-1587. | 1.3 | 0 |
| 157 | Reply. Liver Transplantation, 2020, 26, 1541-1542. | 1.3 | 0 |
| 158 | REPLY:. Hepatology, 2021, 74, 2916-2917. | 3.6 | 0 |
| 159 | Management of Ascites. , 2020, , 11-30. | | 0 |
| 160 | Historical Aspects of Ascites and the Hepatorenal Syndrome. Clinical Liver Disease, 2021, 18, 14-27. | 1.0 | 0 |
| 161 | Cirrhosis; Acute Kidney Injury. , 2020, , 514-525. | | 0 |